Dapagliflozin for attenuating early anthracycline-associated cardiac changes (DAPA-AIC): a randomized, double-blind, placebo-controlled trial
A diabetes drug showed promise in reducing early heart damage during chemotherapy, warranting larger studies to confirm potential benefits.
AIMS: To evaluate whether dapagliflozin attenuates early cardiac functional and biomarker changes during anthracycline-based chemotherapy. These findings suggest that dapagliflozin may help attenuate early anthracycline-associated cardiac changes, although larger and longer studies are needed to confirm its clinical benefits and safety.
What the study was
- Study design
- Randomized Controlled Trial
- Population
- AIMS: To evaluate whether dapagliflozin attenuates early cardiac functional and biomarker changes du
- Category
- Genomics/Precision Medicine
- Maturity
- Potentially Practice-Changing
- Journal
- Future science OA
Why it surfaced
RCT design; high triage score
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.